Norway vs Sur: Previously treated cases tested for RR-/MDR-TB
Norway
100.0%
in 2024
Sur
62.0%
in 2024
Norway rank
1st
Sur rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Norway
- Sur
How they compare
Norway currently reports 100.0% against 62.0% in Sur, a difference of 38.0%.
That makes Norway's figure about 1.6 times Sur's.
The two have swapped places 8 times across 17 shared years of data; in 2005 it was Norway ahead.
Norway ranks 1st and Sur ranks 1st of 180 countries.
Norway has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Norway | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 58.7% | 14.3% | 44.3% | Norway |
| 2010s | 60.0% | 53.0% | 7.0% | Norway |
| 2020s | 89.4% | 78.4% | 11.0% | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Norway or Sur?
- Norway, at 100.0% against 62.0% in Sur as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Norway and Sur?
- 38.0%, with Norway ahead.
- How many years of comparable data are there for Norway and Sur?
- 17 years are reported by both, from 2005 to 2024.
- How do Norway and Sur rank globally for previously treated cases tested for rr-/mdr-tb?
- Norway ranks 1st and Sur ranks 1st of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.